An Ancient Virus Infecting Residents Across Australia’s Northern Territory is Leaving Death and Despair in its Path!

“The prevalence is off the charts” in Australia, said Dr. Robert Gallo, co-founder and director of the Institute of Human Virology at the University of Maryland School of Medicine, whose laboratory was the first to detect HTLV-1 in 1979 and publish the finding in 1980.
Yet “nobody that I know of in the world has done anything about trying to treat this disease before,” said Gallo, who is also co-founder and scientific director of the Global Virus Network and chairs the network’s HTLV-1 Task Force.
“There’s little to almost no vaccine efforts, outside of some Japanese research,” he said. “So prevention by vaccine is wide open for research.”

HTLV-1 is a human retrovirus that mainly infects the CD4+ T cell. Such Infections can lead to a host of immune-related diseases including leukemia. Somewhat counterintuitively, the virus thrives by remaining at very low levels in the body, which is unlike its more notorious cousin, HIV.

READ  Tech firms unveil anti-disinformation code in Australia as call for action follows government inquiries

“HTLV-1 RNA is rarely detected in the plasma of infected individuals, and it persists by evading host immune surveillance,” says Jun-ichirou Yasunaga of Kyoto University’s Institute for Frontier Life and Medical Sciences, who led the study.

Lymphadenopathy (swollen lymph nodes)
Nausea and vomiting
Skin and bone abnormalities
Enlarged liver and/or spleen
Frequent infections

Roughly .25-2% of people with HTLV-1 will develop HAM/TSP, a chronic, progressive disease of the nervous system. Signs and symptoms of this condition vary but may include:[2][3]

Progressive weakness
Stiff muscles
Muscle spasms
‘Weak’ bladder

There are approximately 10–20 million HTLV-I carriers in the world

READ  Australia News Calls Out Joe Biden for Cognitive Compromise, The Dementia is Transparently Obvious.

Japan, parts of central Africa, the Caribbean basin and South America. In addition, epidemiological studies of HTLV-I have revealed high seroprevalence rates in Melanesia, Papua New Guinea and the Solomon islands, as well as among Australian aborigines [12]. In Japan, approximately 1.2 million individuals are estimated to be infected by HTLV-I, and more than 800 cases of ATL are diagnosed each year [13]. Moreover, this virus also causes the neurodegenerative disease, HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [14, 15]. The cumulative risks of ATL among HTLV-I carriers in Japan are estimated to be about 6.6% for men and 2.1% for women, indicating that most HTLV-I carriers remain asymptomatic throughout their lives


h/t Goofy for God


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.